ROS1 and non-small cell lung carcinoma: In the same way, Chen and collaborators described the case of a IIIA-NSCLC positive for a novel LDLR-ROS1 fusion who received crizotinib as adjuvant treatment and achieved a recurrence-free survival of 29 months [44].